TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26035186

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Vortioxetine 15 mg
Number of subjects: 469

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Vortioxetine (both doses)
Number of subjects: 469
Study: 23857320

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 2368
Study: 21539650

Group type: EXPERIMENTAL
Intervention: Nutrition intervention (calories in the range of BEE × 1.1 × 1.3 to 1.5, 37.9 ± 6.5 kcal/kg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (29.1 ± 4.9 kcal/kg/day)
Number of subjects: 60
Study: 19179714

Group type: EXPERIMENTAL
Intervention: Sling
Number of subjects: 84

Group type: COMPARATOR
Intervention: No sling
Number of subjects: 84
Study: 17557449

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 0
Study: 15196362

Group type: EXPERIMENTAL
Intervention: Primary duct closure
Number of subjects: 55

Group type: COMPARATOR
Intervention: T‐tube drainage
Number of subjects: 55
Study: 11438132

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg for 14 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9872636

Group type: EXPERIMENTAL
Intervention: Burke and Bowden chart
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oakley chart
Number of subjects: 20
Study: 8577634

Group type: EXPERIMENTAL
Intervention: 14C‐caffeine breath test (C3BT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 14C‐caffeine breath test (C7BT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 20
Study: 2551355

Group type: COMPARATOR
Intervention: 2-drug chemotherapy regimen (cyclophosphamide 10 mg/kg i.v. days 1-4 and vincristine 1 mg i.v. days 1 + 4; every 4 weeks)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 4-drug chemotherapy regimen (cyclophosphamide 10 mg/kg i.v. days 1-3, vincristine 2 mg i.v. day 1 and 1 mg i.v. day 5, methotrexate 30 mg i.v. days 3 and 5, CCNU 80 mg/m2 i.v. day 2; every 7 weeks)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Local radiotherapy (55 Gy/25 fractions/8 weeks)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) 40 Gy/20 fractions/4 weeks
Number of subjects: 55
Study: 332438

Group type: EXPERIMENTAL
Intervention: Trimazosin, 900 mg daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Methyldopa, 2,250 mg daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31587885

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg intravenously)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 27049354

Group type: EXPERIMENTAL
Intervention: Povidone iodine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 26211623

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23275404

Group type: EXPERIMENTAL
Intervention: 5 weekly doses of milieu communication teaching (MCT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 1 weekly dose of milieu communication teaching (MCT)
Number of subjects: 64
Study: 22024276

Group type: EXPERIMENTAL
Intervention: Circulating Lp‐PLA2 levels
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Plaque volume (PV)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: % change in PV
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: % changes in Lp‐PLA2 and PV
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Absolute change in PV
Number of subjects: 40
Study: 19517231

Group type: EXPERIMENTAL
Intervention: Havrix (HAV) vaccine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TWINRIX (HAV/HBV combination vaccine)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Engerix (HBV) vaccine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combined HAV/HBV vaccination
Number of subjects: 84
Study: 17197592

Group type: EXPERIMENTAL
Intervention: 1% lidocaine intracervical block
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intracervical saline injection
Number of subjects: 120

Group type: COMPARATOR
Intervention: No injection
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine group
Number of subjects: 120
Study: 15851169

Group type: EXPERIMENTAL
Intervention: Epinephrine test
Number of subjects: 42
Study: 11190900

Group type: EXPERIMENTAL
Intervention: G20210A prothrombin gene mutation prevalence in women with recurrent miscarriage
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (healthy parous women)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Caucasian patient group
Number of subjects: 122

Group type: COMPARATOR
Intervention: Caucasian control group
Number of subjects: 122
Study: 9635947

Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or =90 mm Hg
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or =85 mm Hg
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or =80 mm Hg
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 75 mg/day
Number of subjects: 18790

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Target group < or =80 mm Hg vs target group < or =90 mm Hg (in patients with diabetes mellitus)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure at mean achieved 82.6 mm Hg
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure at 86.5 mm Hg
Number of subjects: 18790
Study: 8162627

Group type: EXPERIMENTAL
Intervention: Colestipol 10 g and Simvastatin 10 mg/day (CS)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Colestipol 10 g and Bezafibrate 400 mg/day (CB)
Number of subjects: 33
Study: 2735338

Group type: EXPERIMENTAL
Intervention: Sucralfate tablets
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sucralfate suspension
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 75
Study: 4985836

Group type: EXPERIMENTAL
Intervention: 5 ml. of packed group O R(2)R(2) cells, administered by intravenous injection
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0.5 ml. of packed group O R(2)R(2) cells, administered by intravenous injection
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Initial antibodies comprised 7S gammaG immunoglobulins with a minor 19S gammaM component in about half the cases
Number of subjects: 11
Study: 31033903

Group type: EXPERIMENTAL
Intervention: Interactive Virtual Reality (I-VR) during high-intensity cycling
Number of subjects: 94

Group type: COMPARATOR
Intervention: Static VR/motor imagery control
Number of subjects: 94
Study: 28167660

Group type: EXPERIMENTAL
Intervention: Eliglustat
Number of subjects: 157
Study: 25831102

Group type: EXPERIMENTAL
Intervention: 2% CHX
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 10% NaOCl
Number of subjects: 36

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Biofilm without cariogenic challenge
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Biofilm with cariogenic challenge
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 18-month water storage
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 24h control
Number of subjects: 36
Study: 23121681

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 90

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 90
Study: 22420399

Group type: EXPERIMENTAL
Intervention: DynaClose topical tissue expansion device
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Local full-thickness skin graft closure
Number of subjects: 25

Group type: COMPARATOR
Intervention: Patient assessment of cosmesis
Number of subjects: 25

Group type: COMPARATOR
Intervention: Michigan Hand Outcomes Questionnaire scores
Number of subjects: 25
Study: 18753738

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg orally t.i.d.)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 17994436

Group type: EXPERIMENTAL
Intervention: Azithromycin, single 1 gram dose
Number of subjects: 1452

Group type: COMPARATOR
Intervention: Topical tetracycline, twice per day for six weeks
Number of subjects: 1452
Study: 15487810

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg every 12 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg once daily plus gemfibrozil 600 mg every 12 hours
Number of subjects: 12
Study: 11571454

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 3x1 g/day for 14 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: No preemptive treatment (Control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir 2x5 mg/kg body weight for 14 days (for those who developed CMV disease)
Number of subjects: 60
Study: 9804594

Group type: EXPERIMENTAL
Intervention: Cocaine administration (0.4 mg/kg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 5
Study: 7822675

Group type: EXPERIMENTAL
Intervention: Daily Disposable Wear (DDW)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Conventional Daily Wear (CDW)
Number of subjects: 195
Study: 3361417

Group type: EXPERIMENTAL
Intervention: Value self-confrontation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Group discussion
Number of subjects: 87

Group type: COMPARATOR
Intervention: Non-treatment control
Number of subjects: 87
Study: 31711465

Group type: EXPERIMENTAL
Intervention: Decrease in BMI (2.5-4.9%)
Number of subjects: 81388

Group type: EXPERIMENTAL
Intervention: Decrease in BMI (5.0-9.9%)
Number of subjects: 81388

Group type: EXPERIMENTAL
Intervention: Decrease in BMI (10.0-14.9%)
Number of subjects: 81388

Group type: EXPERIMENTAL
Intervention: Decrease in BMI (≥ 15.0%)
Number of subjects: 81388

Group type: EXPERIMENTAL
Intervention: Every 5% decrease in BMI
Number of subjects: 81388

Group type: COMPARATOR
Intervention: Stable BMI
Number of subjects: 81388
Study: 30334914

Group type: EXPERIMENTAL
Intervention: Spreader flap with triangular spreader graft (group 3)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Spreader flap with rectangular spreader graft (group 2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Spreader flap (group 1)
Number of subjects: 36
Study: 26865198

Group type: EXPERIMENTAL
Intervention: Good adherence (cumulative medication adherence, ≥80%)
Number of subjects: 33728

Group type: EXPERIMENTAL
Intervention: Poor adherence (cumulative medication adherence, <50%)
Number of subjects: 33728

Group type: EXPERIMENTAL
Intervention: Intermediate adherence (cumulative medication adherence, 50%-80%)
Number of subjects: 33728

Group type: EXPERIMENTAL
Intervention: Poor medication adherence
Number of subjects: 33728
Study: 25190615

Group type: EXPERIMENTAL
Intervention: Enteral potassium replacement (EPR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous potassium replacement (IVPR)
Number of subjects: 0
Study: 21979104

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both Propofol and Sevoflurane
Number of subjects: 40
Study: 19046051

Group type: EXPERIMENTAL
Intervention: Chlorhexidine showers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no chlorhexidine showers)
Number of subjects: 0
Study: 17218552

Group type: EXPERIMENTAL
Intervention: Inhaled tiotropium
Number of subjects: 1829
Study: 15367512

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg/day
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1658
Study: 11211063

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9554820

Group type: EXPERIMENTAL
Intervention: s.c. rHu‐EPO (2000 U/twice weekly)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: s.c. rHu‐EPO (3000 U twice weekly after 6 weeks if Hb increase was below 1 g%)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: s.c. rHu‐EPO therapy
Number of subjects: 84
Study: 8060471

Group type: COMPARATOR
Intervention: Cyclosporin and prednisolone (double therapy)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Cyclosporin, prednisolone, and azathioprine (triple therapy)
Number of subjects: 195
Study: 3137765

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30920593

Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: PET-directed focal therapy
Number of subjects: 635
Study: 28633774

Group type: EXPERIMENTAL
Intervention: Noninvasive interactive neurostimulation (NIN)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Electric shockwave therapy
Number of subjects: 104
Study: 25196721

Group type: EXPERIMENTAL
Intervention: Arm ergometer exercise training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Strengthening range-of-motion (ROM) exercise program
Number of subjects: 24
Study: 24111257

Group type: EXPERIMENTAL
Intervention: Low workload (WKL) condition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High workload (WKL) condition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Short time on task (TOT) condition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Long time on task (TOT) condition
Number of subjects: 20
Study: 21438131

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIP/TAZO) 125 mg/kg every 8 hr
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cefozopran (CZOP) 25 mg/kg every 6 hr
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both PIP/TAZO and CZOP
Number of subjects: 49
Study: 19569068

Group type: EXPERIMENTAL
Intervention: Facilitated PCI (high-dose tirofiban)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Primary PCI (control)
Number of subjects: 39
Study: 17826502

Group type: EXPERIMENTAL
Intervention: InhibiZone-coated IPPs in virgin nondiabetic patients
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: InhibiZone-coated IPPs in virgin diabetic patients
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: InhibiZone-coated IPPs in revision patients without washout
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: InhibiZone-coated IPPs in revision patients with antiseptic washout
Number of subjects: 467

Group type: COMPARATOR
Intervention: Noncoated IPPs (historical control)
Number of subjects: 467
Study: 15571635

Group type: EXPERIMENTAL
Intervention: Natural mineral water
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Magnesium enriched water
Number of subjects: 70

Group type: COMPARATOR
Intervention: Water low in minerals
Number of subjects: 70
Study: 11071026

Group type: EXPERIMENTAL
Intervention: Latanoprost, 50 microg/ml once daily
Number of subjects: 164

Group type: COMPARATOR
Intervention: Timolol 5 mg/ml plus dorzolamide, 20 mg/ml twice daily
Number of subjects: 164
Study: 9071196

Group type: EXPERIMENTAL
Intervention: Early reperfusion therapy (within six hours)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Late reperfusion therapy (after six hours)
Number of subjects: 301
Study: 8370002

Group type: EXPERIMENTAL
Intervention: Interactive videodisc (IVD) simulation before clinical experience (Group 1, n = 18)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Traditional clinical experience first (Group 2, n = 21)
Number of subjects: 39
Study: 2425315

Group type: EXPERIMENTAL
Intervention: Epidural hydromorphone (1.0 mg in 10 mL preservative-free saline)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Epidural bupivacaine (10 mL of 0.25%)
Number of subjects: 52
Study: 31525795

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Cocktail of medications (CO)
Number of subjects: 189
Study: 31931137

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 693
Study: 28866140

Group type: EXPERIMENTAL
Intervention: Encapsulated fruit and vegetable juice powder concentrate (JuicePlus+®)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 27511740

Group type: EXPERIMENTAL
Intervention: Individual standardized reminiscence therapy performed by trained nursing home volunteers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 24499473

Group type: EXPERIMENTAL
Intervention: Higher brand equity from the antidrug campaign
Number of subjects: 0
Study: 22520526

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES-R)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 51
Study: 20135251

Group type: EXPERIMENTAL
Intervention: MRI diagnostics of TMJ
Number of subjects: 58
Study: 18835314

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (15 mg retinol equivalent) alongside the pentavalent vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no vitamin A supplementation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation with pentavalent vaccine
Number of subjects: 0
Study: 16681880

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/d
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: Aspirin 80 mg/d
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/d (HNPCC)
Number of subjects: 28
Study: 12831221

Group type: EXPERIMENTAL
Intervention: Function regulator (FR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 18
Study: 11784351

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9369038

Group type: EXPERIMENTAL
Intervention: LDL‐apheresis plus simvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional drug treatment alone
Number of subjects: 0
Study: 8249557

Group type: EXPERIMENTAL
Intervention: isoflurane
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: halothane
Number of subjects: 12
Study: 3514233

Group type: EXPERIMENTAL
Intervention: Cisapride (slow i.v. injection)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (slow i.v. injection)
Number of subjects: 9
Study: 29309089

Group type: EXPERIMENTAL
Intervention: One-on-one in-person consultation to discuss CRC screening and the screening process, as well as a FIT.
Number of subjects: 3415

Group type: EXPERIMENTAL
Intervention: Telephone call to discuss CRC screening and the screening process before receiving a FIT in the mail.
Number of subjects: 3415

Group type: COMPARATOR
Intervention: Control group: Patients who were mailed a FIT with a letter explaining the importance of completing the FIT and instructions.
Number of subjects: 3415
Study: 26780376

Group type: EXPERIMENTAL
Intervention: BR decision support aid
Number of subjects: 55

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 55
Study: 24852301

Group type: EXPERIMENTAL
Intervention: Nurse-led psychoeducational intervention plus usual care
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 300
Study: 22494043

Group type: EXPERIMENTAL
Intervention: New irrigation design catheter (group A, 40 patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard irrigated catheter (group B, 40 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: New irrigation design catheter (group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intraprocedural ACT
Number of subjects: 80
Study: 20417153

Group type: EXPERIMENTAL
Intervention: S1-root stimulation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tibial nerve stimulation
Number of subjects: 55

Group type: COMPARATOR
Intervention: L4/L5-level stimulation
Number of subjects: 55
Study: 18581440

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 270
Study: 15836533

Group type: EXPERIMENTAL
Intervention: Intensive patient education (one-on-one session by primary care nurses, 2-page handout on CRC screening)
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Intensive patient education
Number of subjects: 788

Group type: COMPARATOR
Intervention: Standard patient education (FOBT cards and written instructions from manufacturer)
Number of subjects: 788

Group type: COMPARATOR
Intervention: Standard patient education
Number of subjects: 788
Study: 11480744

Group type: EXPERIMENTAL
Intervention: Evidence-based care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational, descriptive, and qualitative methods
Number of subjects: 0
Study: 9778331

Group type: EXPERIMENTAL
Intervention: Atrioverter
Number of subjects: 51
Study: 8164028

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate (1.8, 2.4, 3.0, and 5.0 mg/kg) administered intravenously over 20 minutes, starting 30 minutes before chemotherapy.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate (doses > 2.4 mg/kg)
Number of subjects: 89
Study: 3415894

Group type: EXPERIMENTAL
Intervention: Graduated training programme
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 32
Study: 1920009

Group type: EXPERIMENTAL
Intervention: Sustained release delivery of chlorhexidine (SRD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Routine maintenance therapy (RMT)
Number of subjects: 10
Study: 582685

Group type: EXPERIMENTAL
Intervention: L-tryptophane plus oxprenolol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31519283

Group type: EXPERIMENTAL
Intervention: Quercetin 500 mg/day for 12 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Starch placebo 500 mg/day for 12 weeks
Number of subjects: 84
Study: 28095099

Group type: EXPERIMENTAL
Intervention: Exercise-nutritional supplement program (ENP)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Health education program (SAP)
Number of subjects: 121
Study: 25555385

Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Content Cigarettes (RNC)
Number of subjects: 51